These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18157009

  • 21. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE.
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [Abstract] [Full Text] [Related]

  • 22. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
    Bequet-Romero M, Ayala M, Acevedo BE, Rodríguez EG, Ocejo OL, Torrens I, Gavilondo JV.
    Angiogenesis; 2007 Apr; 10(1):23-34. PubMed ID: 17273909
    [Abstract] [Full Text] [Related]

  • 23. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 24. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
    Khallouf H, Märten A, Serba S, Teichgräber V, Büchler MW, Jäger D, Schmidt J.
    J Immunother; 2012 Apr 01; 35(3):245-53. PubMed ID: 22421942
    [Abstract] [Full Text] [Related]

  • 25. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
    Wang J, Shi YQ, Yi J, Ye S, Wang LM, Xu YP, He M, Kong XM.
    J Dig Dis; 2008 Nov 01; 9(4):228-37. PubMed ID: 18959596
    [Abstract] [Full Text] [Related]

  • 26. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
    Zhang X, Xu J, Lawler J, Terwilliger E, Parangi S.
    Clin Cancer Res; 2007 Jul 01; 13(13):3968-76. PubMed ID: 17606731
    [Abstract] [Full Text] [Related]

  • 27. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
    Tóvári J, Gilly R, Rásó E, Paku S, Bereczky B, Varga N, Vágó A, Tímár J.
    Cancer Res; 2005 Aug 15; 65(16):7186-93. PubMed ID: 16103069
    [Abstract] [Full Text] [Related]

  • 28. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
    Shang D, Ito N, Watanabe J, Awakura Y, Nishiyama H, Kamoto T, Ogawa O.
    Eur Urol; 2007 Oct 15; 52(4):1131-9. PubMed ID: 17275163
    [Abstract] [Full Text] [Related]

  • 29. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
    Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Cruz-Correa M, Blayney DW, Ensminger WD, St Croix B, Dang NH, Dang LH.
    Cancer Res; 2008 Mar 15; 68(6):1872-80. PubMed ID: 18339868
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW, Bruns CJ.
    Oncogene; 2008 Dec 04; 27(57):7212-22. PubMed ID: 18794807
    [Abstract] [Full Text] [Related]

  • 31. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
    Avnet S, Cenni E, Perut F, Granchi D, Brandi ML, Giunti A, Baldini N.
    Int J Oncol; 2007 Feb 04; 30(2):469-76. PubMed ID: 17203230
    [Abstract] [Full Text] [Related]

  • 32. Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1alpha in Ehrlich ascites tumor cells.
    Kumar A, D'Souza SS, Nagaraj SR, Gaonkar SL, Salimath BP, Rai KM.
    Cancer Chemother Pharmacol; 2009 Nov 04; 64(6):1221-33. PubMed ID: 19370348
    [Abstract] [Full Text] [Related]

  • 33. Antiangiogenic activity of Andrographis paniculata extract and andrographolide.
    Sheeja K, Guruvayoorappan C, Kuttan G.
    Int Immunopharmacol; 2007 Feb 04; 7(2):211-21. PubMed ID: 17178389
    [Abstract] [Full Text] [Related]

  • 34. A low molecular weight polysaccharide isolated from Agaricus blazei suppresses tumor growth and angiogenesis in vivo.
    Niu YC, Liu JC, Zhao XM, Wu XX.
    Oncol Rep; 2009 Jan 04; 21(1):145-52. PubMed ID: 19082455
    [Abstract] [Full Text] [Related]

  • 35. Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer.
    Tjomsland V, El-Salhy M.
    Int J Oncol; 2005 Aug 04; 27(2):427-32. PubMed ID: 16010424
    [Abstract] [Full Text] [Related]

  • 36. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity.
    Watanabe H, Mamelak AJ, Wang B, Howell BG, Freed I, Esche C, Nakayama M, Nagasaki G, Hicklin DJ, Kerbel RS, Sauder DN.
    Exp Dermatol; 2004 Nov 04; 13(11):671-81. PubMed ID: 15500639
    [Abstract] [Full Text] [Related]

  • 37. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

  • 38. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
    Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J, Xie K.
    Cancer Res; 2007 May 15; 67(10):4878-85. PubMed ID: 17510417
    [Abstract] [Full Text] [Related]

  • 39. Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch.
    Lee H, Baek S, Joe SJ, Pyo SN.
    Int Immunopharmacol; 2006 Jan 15; 6(1):71-8. PubMed ID: 16332515
    [Abstract] [Full Text] [Related]

  • 40. Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice.
    Ho JC, Konerding MA, Gaumann A, Groth M, Liu WK.
    Life Sci; 2004 Jul 30; 75(11):1343-56. PubMed ID: 15234192
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.